非转移性非小细胞肺癌 (NSCLC) 与驱动基因变异的管理:一个不断发展的情景
Valeria Fuorivia1, Ilaria Attili2, Carla Corvaja2
1Division of Thoracic Oncology, European Institute of Oncology IRCCS, 20141 Milan, Italy.
Current oncology (Toronto, Ont.)
|September 27, 2024
概括
针对性疗法,如奥西默提尼布和阿莱克提尼布正在改善非小细胞肺癌 (NSCLC) 患者的治疗结果,这些患者没有远程传播. 早期的分子测试对于指导这些先进的非转移性NSCLC治疗至关重要.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 非小细胞肺癌 (NSCLC) 的治疗正在发展,特别是对于非转移性疾病.
- 免疫疗法是可切除的NSCLC没有EGFR突变或ALK重组的标准.
- 针对特定驱动基因改变的NSCLC,有针对性的疗法正在出现.
研究的目的:
- 审查针对非转移性NSCLC的向治疗的证据.
- 总结正在进行的EGFR和ALK以外可操作的基因变异试验.
- 突出分子测试在早期NSCLC管理中的重要性.
主要方法:
- 对非转移性NSCLC的向疗法临床数据的系统审查.
- 对辅助和新辅助治疗结果的分析.
- 目前正在进行的临床试验的结果摘要.
主要成果:
- 辅助性 osimertinib (3年) 改善了 DFS,OS,并减少了EGFR突变NSCLC (IB-IIIA阶段) 中的中枢神经系统复发.
- 化学辐射后的奥西默提尼布改善了EGFR突变性NSCLC (第三阶段) 无法切除的PFS.
- 阿莱克提尼布 (2年) 显著改善了ALK阳性NSCLC (IB-IIIA阶段) 的DFS与化疗相比.
结论:
- 向疗法正在改变对具有可操作突变的患者的非转移性NSCLC治疗.
- 目前正在进行的试验正在探索TKI的最佳持续时间和新辅助策略.
- 早期和全面的分子分析对于个性化NSCLC治疗决策至关重要.
关键词:
在NSCLCLC中,我们可以看到.一个辅助的辅助者.基因驱动器基因驱动器在早期的早期阶段.在本地先进的先进.这是一种新辅助剂.在外科手术期间的外科手术.有针对性的治疗.氨酸激酶抑制剂 (TKI) 的使用更多相关视频
11:15Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.3K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.8K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K